Idarubicine

Elderly Patients

Chinese PLA General HospitalPhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 81/ 100

Competitive context

15 Active assets in the Elderly Patients cohort.

Asset / Sponsor	Phase	Rating
Capecitabine GERCOR - Multidisciplinary Oncology Cooperative Group	Phase 3	B
NORETHANDROLONE University Hospital, Grenoble	Phase 3	B
ROPIVACAINE University Hospital, Clermont-Ferrand	Phase 2	B
Cyclophosphamide Fondazione Italiana Linfomi - ETS	Phase 3	B
VITAMIN D Fondazione Italiana Linfomi - ETS	Phase 3	B

View all 26 →

Same molecule, other indications

Idarubicine is also rated in:

acute promyelocytic leukemiaDormant

A

Indicative ·

81 / 100

Acute Promyelocytic LeukemiaDormant

BBB

Indicative ·

78 / 100

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant

BBB

Indicative ·

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.